Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drusen complement components C3a and C5a promote choroidal neovascularization.

Miho Nozaki1, Brian J Raisler, Eiji Sakurai

  • 1Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington, KY 40536, USA.

Proceedings of the National Academy of Sciences of the United States of America
|February 3, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Repurposing Purine Analog Antivirals to Modulate Serum Uric Acid: Evidence From Real-World Data.

Clinical and translational science·2026
Same author

Acute cardiovascular events after discontinuation of xanthine oxidase inhibitors: a cohort study.

Clinical rheumatology·2025
Same author

Brillouin Optical Spectroscopy for In Vivo and Ex Vivo Assessment of Corneal Biomechanics.

Cornea·2025
Same author

Oral lamivudine in diabetic macular edema: A randomized, double-blind, placebo-controlled clinical trial.

Med (New York, N.Y.)·2025
Same author

Association of nucleoside reverse transcriptase inhibitor use with reduced risk of Alzheimer's disease risk.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

NLRP3 Activation With Bisphosphonate Use and the Risk of Incident Age-Related Macular Degeneration.

Investigative ophthalmology & visual science·2025

Complement fragments C3a and C5a in drusen drive age-related macular degeneration (AMD) by inducing VEGF. Blocking these fragments reduces choroidal neovascularization (CNV), offering new therapeutic targets for AMD.

Area of Science:

  • Ophthalmology
  • Immunology
  • Molecular Biology

Background:

  • Age-related macular degeneration (AMD) is a leading cause of irreversible blindness.
  • Drusen, extracellular deposits, are early hallmarks of AMD and precede choroidal neovascularization (CNV).
  • Complement components C3 and C5 are found in AMD retinas, suggesting a role in disease pathogenesis.

Purpose of the Study:

  • To investigate the role of complement fragments C3a and C5a in AMD pathogenesis.
  • To determine if C3a and C5a contribute to drusen formation and CNV.
  • To explore C3a and C5a as potential therapeutic targets for AMD.

Main Methods:

  • Analysis of drusen from AMD patients for C3a and C5a presence.
  • In vitro and in vivo studies assessing C3a and C5a's effect on VEGF expression.

Related Experiment Videos

  • Laser-induced CNV mouse model to evaluate the impact of C3a/C5a receptor blockade.
  • Genetic ablation and antibody neutralization of C3a/C5a and their receptors.

    • Main Results:

    • Bioactive C3a and C5a fragments were detected in AMD drusen.
    • C3a and C5a induced VEGF expression in vitro and in vivo.
    • Genetic or pharmacological blockade of C3a/C5a receptors reduced VEGF, leukocyte recruitment, and CNV formation in a laser-induced CNV model.

    Conclusions:

    • C3a and C5a play a mechanistic role in linking drusen to CNV development in AMD.
    • These complement fragments promote angiogenesis via VEGF induction.
    • Targeting C3a and C5a pathways offers a promising therapeutic strategy for AMD.